KLDO.US Kaleido Biosciences Inc

Healthcare Pharmaceuticals USA Stocks
0.0001 USD
Close of Nov 15, 2026
Market cap
USD 4.26K
P/E
-
P/B
0.00x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.

Is KLDO.US undervalued?

Graham number

The Graham number of Kaleido Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kaleido Biosciences Inc fundamental analysis

No fundamental analysis for Kaleido Biosciences Inc yet.

Kaleido Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kaleido Biosciences Inc

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncolog…

Full company profile